Public disclosures

Equels Thomas K

Company insiders · CEO & President · Director · AIM ImmunoTech Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-20.Following & alerts
Reported transaction lines
8
Buy lines
8
Sell lines
0

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-118

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 436095 · SEC code covers open-market or private transactions

2026-11-192026-11-20

≈ $6,550.00

50,000 shares/units

SEC 4
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 386095 · SEC code covers open-market or private transactions

2026-11-182026-11-18

≈ $2,680.00

20,000 shares/units

SEC 4
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 366095 · SEC code covers open-market or private transactions

2026-11-162026-11-17

≈ $5,130.00

38,000 shares/units

SEC 4
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 328095 · SEC code covers open-market or private transactions

2026-11-112026-11-13

≈ $5,215.00

35,000 shares/units

SEC 4
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 293095 · SEC code covers open-market or private transactions

2026-11-102026-11-12

≈ $5,382.00

39,000 shares/units

SEC 4
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 254095 · SEC code covers open-market or private transactions

2026-11-092026-11-10

≈ $5,070.28

31,298 shares/units

SEC 4
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 222797 · SEC code covers open-market or private transactions

2026-11-062026-11-09

≈ $2,014.66

12,751 shares/units

SEC 4
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 210046 · SEC code covers open-market or private transactions

2026-11-062026-11-06

≈ $3,166.64

20,299 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement